NAMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NewAmsterdam Pharma Company NV (NAMS) is not a strong buy for a beginner investor with a long-term strategy at this moment. The technical indicators are neutral to bearish, options data suggests moderate sentiment, and the company’s financial performance shows significant revenue decline despite some improvement in net income and EPS. While analysts have raised price targets and maintain positive ratings, the lack of recent news, weak technical momentum, and absence of strong trading signals make it prudent to hold off on buying for now.
The MACD histogram is negative (-0.57) and expanding downward, indicating bearish momentum. RSI is at 26.562, which is neutral but approaching oversold territory. Moving averages are converging, showing no clear trend. The stock is trading below the pivot level (33.412) and close to the first support level (30.65), suggesting limited upside potential in the short term.
Analysts have raised price targets recently, with Guggenheim increasing the target to $45 and RBC Capital to $47, both maintaining positive ratings. Management has expressed confidence in the progress of the Phase 3 CVOT PREVAIL trial, which could be a long-term growth driver.
The company’s Q3 2025 financials show a dramatic revenue decline (-98.80% YoY), which raises concerns about its operational performance. Technical indicators are neutral to bearish, and there is no recent news or significant trading activity from insiders or hedge funds to act as a catalyst.
In Q3 2025, revenue dropped significantly by -98.80% YoY to $348,000, raising concerns about the company’s ability to generate sales. However, net income improved to -$72,005,000 (up 332.54% YoY), and EPS increased to -0.61 (up 238.89% YoY). Gross margin remained stable at 100%. While there are signs of improvement in profitability metrics, the revenue decline is a major concern.
Analysts are bullish on the stock, with Guggenheim and RBC Capital raising price targets to $45 and $47, respectively, and maintaining Buy/Outperform ratings. However, these ratings are based on long-term trial progress and not immediate performance.
